
Defining Treatment Success in MG
Successful MG treatment begins with defining what improvement means to the patient and revisiting those goals as disease control evolves. Supported by Vor Bio Medical Affairs.
Episodes in this series

In ‘Defining Treatment Success in MG,’ our panel explores how clinicians can establish realistic expectations when initiating newer therapies and how the definition of treatment success has evolved. Expert faculty emphasize beginning with the patient's own priorities and distinguishing short-term goals from longer-term objectives.
The panel discusses counseling patients about how quickly a therapy may work, the adverse effects or trade-offs associated with different approaches, and what alternative strategies may be considered if the disease or treatment response changes. Setting these expectations in advance may help patients understand the treatment trajectory and reduce uncertainty when improvement is not immediate.
The experts also examine how success in MG has evolved from preventing mortality and severe disability toward achieving minimal or no meaningful symptoms with the lowest feasible burden of treatment. Minimal manifestation status and low MG-ADL scores are discussed as useful clinical benchmarks, while faculty caution that numerical measures alone may not capture treatment burden, financial effects, social consequences, or the patient's perception of normal function.
Treatment response is described as a dynamic process rather than a fixed endpoint. Panelists discuss incorporating formal clinical scores, patient-reported outcomes, and simple questions about how frequently patients are reminded of their MG in everyday life. They also caution that patients with slowly progressive disease may adapt to impairment and consider a reduced level of function their “normal,” making objective and longitudinal assessment particularly important.
Our next episode, ‘Managing Inadequate Response and Monitoring in MG,’ examines when insufficient improvement should prompt a change in strategy and what clinicians are learning about monitoring patients receiving B-cell–directed therapies.
Related to this article








